Harvard Bioscience, Inc. provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing.
Fair value with moderate growth potential.
Share Price & News
How has Harvard Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HBIO's share price has been volatile over the past 3 months.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: HBIO underperformed the US Life Sciences industry which returned 20% over the past year.
Return vs Market: HBIO exceeded the US Market which returned 3.7% over the past year.
Price Volatility Vs. Market
How volatile is Harvard Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAre Investors Undervaluing Harvard Bioscience, Inc. (NASDAQ:HBIO) By 50%?
1 month ago | Simply Wall StImagine Owning Harvard Bioscience (NASDAQ:HBIO) While The Price Tanked 62%
1 month ago | Simply Wall StHarvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Is Harvard Bioscience undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HBIO ($2.66) is trading below our estimate of fair value ($4.56)
Significantly Below Fair Value: HBIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HBIO is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.
PE vs Market: HBIO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HBIO is good value based on its PB Ratio (1.3x) compared to the US Life Sciences industry average (5.6x).
How is Harvard Bioscience forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HBIO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: HBIO is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HBIO's is expected to become profitable in the next 3 years.
Revenue vs Market: HBIO's revenue (8% per year) is forecast to grow slower than the US market (8.9% per year).
High Growth Revenue: HBIO's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HBIO is forecast to be unprofitable in 3 years.
How has Harvard Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HBIO is currently unprofitable.
Growing Profit Margin: HBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare HBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HBIO is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.6%).
Return on Equity
High ROE: HBIO has a negative Return on Equity (-8.99%), as it is currently unprofitable.
How is Harvard Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: HBIO's short term assets ($48.2M) exceed its short term liabilities ($23.5M).
Long Term Liabilities: HBIO's short term assets ($48.2M) do not cover its long term liabilities ($56.8M).
Debt to Equity History and Analysis
Debt Level: HBIO's debt to equity ratio (65.6%) is considered high.
Reducing Debt: HBIO's debt to equity ratio has increased from 24.2% to 65.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HBIO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HBIO is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 25.2% per year.
What is Harvard Bioscience's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Jim Green (61yo)
Mr. James W. Green, also known as Jim, has been Chairman of Harvard Bioscience, Inc. since June 5, 2017 and has been its Independent Director since April 30, 2015. He serves as President and Chief Executiv ...
CEO Compensation Analysis
Compensation vs Market: Jim's total compensation ($USD2.71M) is above average for companies of similar size in the US market ($USD595.62K).
Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.
|Independent Director||19.58yrs||US$149.18k||0.79% $807.4k|
|Independent Director||0.67yr||US$147.45k||0.093% $95.0k|
|Lead Independent Director||0.83yr||US$152.13k||0.65% $668.6k|
|Independent Director||2.58yrs||US$136.50k||0.19% $194.9k|
|Independent Director||2.58yrs||US$132.96k||0.24% $242.7k|
|Independent Director||0.083yr||no data||no data|
Experienced Board: HBIO's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HBIO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Harvard Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Harvard Bioscience, Inc.
- Ticker: HBIO
- Exchange: NasdaqGM
- Founded: 1901
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$102.092m
- Shares outstanding: 38.38m
- Website: https://www.harvardbioscience.com
Number of Employees
- Harvard Bioscience, Inc.
- 84 October Hill Road
- Suite 10
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HBIO||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2000|
|HBI||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2000|
Harvard Bioscience, Inc. provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands. It also designs, develops, and manufactures precision electrophysiology equipment specializing in patch clamp amplifiers, and manual and automated patch clamp systems under the HEKA brand; manufactures tools for electrophysiology and cell biology research consisting of cell chambers, perfusion and temperature controllers, and microincubation and bio-sensing systems under the Warner Instruments brand; and designs and develops in vivo neural interface systems under the TBSI brand for neuroscience research, primarily in the fields of electrophysiology, psychology, neurology, and pharmacology. In addition, the company is involved in the development and manufacture of precision scientific measuring instrumentation and equipment under the Multi-Channel Systems brand; and physiologic monitoring focused on delivering preclinical products, systems, services, and solutions under the DSI and Buxco brands. It markets its products in approximately 100 countries through sales organizations, Websites, catalogs, and distributors to research scientists at pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/25 08:37|
|End of Day Share Price||2020/05/22 00:00|